Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Autosomal dominant Charcot-Marie-Tooth disease type 2A2 (CMT2A2) is a subtype of Autosomal dominant Charcot-Marie-Tooth disease type 2 characterized by the childhood onset of distal weakness and areflexia (with earlier and more severe involvement of the lower extremities), reduced sensory modalities (primarily pain and temperature sensation), foot deformities, postural tremor, scoliosis and contractures. Optic atrophy, vocal cord palsy with dysphonia, sensorineural hearing loss, spinal cord abnormalities and hydrocephalus have also been reported.
Features include very common findings: Foot dorsiflexor weakness, Abnormal foot morphology, Sensory axonal neuropathy, and Absent Achilles reflex and others; and common findings: Distal sensory impairment, Pes cavus, Hand abnormalities (abnormality of the hand), and Frequent falls and others. 64 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 16 | Steppage gait, Pain, Mental deterioration |
Muscles | 14 | Flexion contracture, Distal muscle weakness, Limb muscle weakness |
Arms and legs | 12 | Limb muscle weakness, Foot dorsiflexor weakness, Abnormal foot morphology |
Ears | 2 | Hearing loss (hearing impairment), Inner ear hearing loss (sensorineural hearing impairment) |
Bones and joints | 2 | Sideways curvature of the spine (scoliosis), Postural tremor |
Eyes | 1 | Damage to the optic nerve (optic atrophy) |
MFN2 hereditary motor and sensory neuropathy (MFN2-HMSN) is a classic axonal peripheral sensorimotor neuropathy characterized by earlier and more severe involvement of the lower extremities than the upper extremities, distal upper-extremity involvement as the neuropathy progresses, and more prominent motor deficits than sensory deficits. MFN2-HMSN can be caused by a heterozygous pathogenic variant (autosomal dominant inheritance) or biallelic pathogenic variants (semi-dominant inheritance or autosomal recessive inheritance). The phenotypes associated with the different modes of inheritance do not differ significantly .
The age at onset and disease progression of MFN2-HMSN vary within and among families; onset ranges from age one year to the sixth decade. Most ind...
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
MFN2 encodes mitofusin 2 (757 aa). Mitochondrial outer membrane GTPase that mediates mitochondrial clustering and fusion. Highest expression in Heart Left Ventricle (173.4 TPM) and Muscle Skeletal (158.4 TPM).
Charcot-Marie-Tooth disease type 2A2 is associated with mutations in the MFN2 gene on chromosome 1.
The MFN2 protein participates in Mitofusins trans-interact linking mitochondria prior to fusion pathway.
MFN2 is classified as a druggable target (Enzyme and Transporter categories) with score 0.0.
Autosomal dominant MFN2-HMSN. Variants in certain amino acid residues are always pathogenic, with no evidence of reduced penetrance or variable expressivity (range of phenotypic expression) despite different amino acid substitutions. Examples of different missense changes observed at the same conserved amino acid residue include p.Arg94Trp/Gln, p.Arg104Glu/Trp, p.Ser249Thr/Cys, p.Trp740Ser/Arg . In contrast, variants in other amino acid residues are associated with variable expressivity (early vs later onset of disease) dependent on the amino acid substitution at the same residue. Autosomal dominant vs autosomal recessive variants. No significant genotype-phenotype correlations can be made.
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
The penetrance for AD MFN2-HMSN is considered to be complete. While some individuals with a heterozygous MFN2 pathogenic variant are asymptomatic and have only mild findings on examination at the time of diagnosis, the disease may prove to be late onset in these instances .
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
Formal diagnostic criteria for MFN2 hereditary motor and sensory neuropathy have not been established.
MFN2 hereditary motor and sensory neuropathy (MFN2-HMSN) should be considered in individuals with the following clinical and neurophysiologic findings. Note: No specific findings distinguish MFN2-HMSN from other inherited hereditary motor and sensory neuropathies.
Clinical findings
Onset before age ten years (although a wide range has been reported)
Involvement of the lower extremities earlier and more severely than the upper extremities
Involvement of the distal upper extremities as the neuropathy progresses
Motor deficits more prominent than sensory deficits
Optic atrophy (~7% in the autosomal dominant form, and ~20% in the autosomal recessive form)
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
All hereditary motor and sensory neuropathy (HMSN) forms in which axonal phenotypes have been reported, including PMP22-HMSN, MPZ-HMSN, and GJB1-HMSN (see GJB1 Disorders) need to be considered in the differential diagnosis of MFN2-HMSN. See Charcot-Marie-Tooth Hereditary Neuropathy Overview. MFN2 pathogenic variants are by far the most common cause of autosomal dominant Charcot-Marie-Tooth disease type 2 (CMT2). As many as one third of all individuals with CMT2 with a positive family history have a pathogenic variant in MFN2 . Thus, testing of MFN2 is probably the first genetic test to consider in families with an axonal neuropathy demonstrating male-to-male transmission.
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
Genetic testing for MFN2 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for Charcot-Marie-Tooth disease type 2A2 has been reported in the published literature.
No approved treatments are currently available for Charcot-Marie-Tooth disease type 2A2. The disease remains an area of unmet medical need.
Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with MFN2 hereditary motor and sensory neuropathy (MFN2-HMSN), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 3. Recommended Evaluations Following Initial Diagnosis in Individuals with MFN2 Hereditary Motor and Sensory Neuropathy
System/Concern | Evaluation | Comment |
|---|---|---|
neuropathy | Neurologic exam | To determine extent of weakness atrophy, pes cavus, gait stability, sensory loss EMG w/NCV |
Musculoskeletal | Orthopedics / physical medicine rehab / PT OT eval | To incl assessment of:; Gross motor fine motor skills need for PT (to improve gross motor skills) /or OT (to improve fine motor skills); Feet for evidence of pes cavus, need for AFOs, specialized shoes; Mobility, ADL, need for adaptive devices; Need for handicapped parking |
Optic atrophy | Ophthalmologic exam incl VEP | To incl visual acuity, color vision testing, visual field testing for evidence of central scotomas Genetic |
counseling | By genetics professionals1 | To obtain a pedigree inform affected persons their families re nature, MOI, implications of MFN2-HMSN to facilitate medical personal decision making Family support resources |
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
Obesity, which makes walking more difficult, should be avoided. Medications that are toxic or potentially toxic to persons with CMT comprise a spectrum of risk ranging from definite high risk to negligible risk. See the Charcot-Marie-Tooth Association website for an up-to-date list.
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions.
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
1 trial found
Table 4. Recommended Surveillance for Individuals with MFN2 Hereditary Motor and Sensory Neuropathy
System/Concern | Evaluation | Frequency |
|---|---|---|
Imaging | MRI of legs to assess amount location of fat replacing muscles1 | Specialized centers only, every few yrs |
Foot exam | For pressure sores or poorly fitting footwear | Annually |
Vision | Those w/o visual manifestations | Routine ophthalmologic exam |
Those w/opticatrophy | Assessment of visual acuity, visual fields | Per treating ophthalmologist Assessment of low vision aids |
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
Phenotype severity distribution: 6 very common features, 18 common features.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
10 publications have been identified in PubMed for Charcot-Marie-Tooth disease type 2A2. Research spans Basic Science / Preclinical (40%), Review / Meta-Analysis (20%), and Case Report / Case Series (20%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 4 | 40% |
Research summaries | 2 | 20% |
Patient case studies | 2 | 20% |
Other research | 1 | 10% |
Testing and diagnosis research | 1 | 10% |
Chu ATW (2026). [PMID: 41720969](https://pubmed.ncbi.nlm.nih.gov/41720969/). *Commun Med (Lond)*. [Other]
Abati E (2026). [PMID: 42020662](https://pubmed.ncbi.nlm.nih.gov/42020662/). *Sci Rep*. [Diagnostic / Biomarker]
Giovenale AMG (2025). [PMID: 40886547](https://pubmed.ncbi.nlm.nih.gov/40886547/). *Stem Cell Res*. [Basic Science / Preclinical]
Zanfardino P (2025). [PMID: 40149969](https://pubmed.ncbi.nlm.nih.gov/40149969/). *Biomolecules*. [Review / Meta-Analysis]
Alekseeva TM (2025). [PMID: 40457678](https://pubmed.ncbi.nlm.nih.gov/40457678/). *Zh Nevrol Psikhiatr Im S S Korsakova*. [Case Report / Case Series]
Rizzuti M (2025). [PMID: 41237781](https://pubmed.ncbi.nlm.nih.gov/41237781/). *Stem Cell Reports*. [Review / Meta-Analysis]
Han Y (2025). [PMID: 39779340](https://pubmed.ncbi.nlm.nih.gov/39779340/). *Zhonghua Yi Xue Yi Chuan Xue Za Zhi*. [Case Report / Case Series]
Kumar A (2024). [PMID: 38883841](https://pubmed.ncbi.nlm.nih.gov/38883841/). *iScience*. [Basic Science / Preclinical]
Zhang Y (2024). [PMID: 39142491](https://pubmed.ncbi.nlm.nih.gov/39142491/). *Int J Biol Macromol*. [Basic Science / Preclinical]
Ferreira T (2024). [PMID: 38549004](https://pubmed.ncbi.nlm.nih.gov/38549004/). *J Neurol*. [Basic Science / Preclinical]
Data assembled from 8 of 12 sources · Last updated Sep 19, 2026, 2:53 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Charcot-Marie-Tooth disease type 2A2
Evaluation |
Frequency Neurologic |
Imaging | MRI of legs to assess amount location of fat replacing muscles1 | Specialized centers only, every few yrs |
Foot exam | For pressure sores or poorly fitting footwear | Annually |
Vision | Those w/o visual manifestations | Routine ophthalmologic exam |
Those w/opticatrophy | Assessment of visual acuity, visual fields | Per treating ophthalmologist Assessment of low vision aids |